EZH1/2 as targets for cancer therapy

被引:24
作者
An, Ran [1 ]
Li, Yu-Qing [1 ]
Lin, Yue-Ling [1 ]
Xu, Fang [2 ]
Li, Man-Mei [2 ]
Liu, Zhong [1 ]
机构
[1] Jinan Univ, Coll Life Sci & Technol, Natl Engn Res Ctr Genet Med, Inst Biomed,Guangdong Prov Key Lab Bioengn Med, Guangzhou 510632, Peoples R China
[2] Jinan Univ, Int Cooperat Lab Tradit Chinese Med Modernizat &, Chinese Minist Educ MOE, Sch Pharm, Guangzhou 510632, Peoples R China
基金
中国国家自然科学基金;
关键词
HISTONE METHYLTRANSFERASE EZH2; SELECTIVE INHIBITOR; PROSTATE-CANCER; LYMPHOMA; POTENT; CELLS; METASTASIS; OVEREXPRESSION; IDENTIFICATION; DEGRADATION;
D O I
10.1038/s41417-022-00555-1
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The enhancer of zeste homolog 2 (EZH2) and its highly related homolog EZH1 are considered to be epigenetic silencing factors, and they play key roles in the growth and differentiation of cells as the core components of polycomb repressive complex 2 (PRC2). EZH1 and EZH2 are known to have a role in human malignancies, and alterations in these two genes have been implicated in transformation of human malignancies. Inhibition of EZH1/2 has been shown to result in tumor regression in humans and has been studied and evaluated in the preclinical setting and in multiple clinical trials at various levels. Our work thus contributes to the understanding of the relationship between regulatory molecules associated with EZH1/2 proteins and tumor progression, and may provide new insights for mechanism-based EZH1/2-targeted therapy in tumors.
引用
收藏
页码:221 / 235
页数:15
相关论文
共 88 条
[1]   p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis [J].
Anwar, Talha ;
Arellano-Garcia, Caroline ;
Ropa, James ;
Chen, Yu-Chih ;
Kim, Hong Sun ;
Yoon, Euisik ;
Grigsby, Sierrah ;
Basrur, Venkatesha ;
Nesvizhskii, Alexey I. ;
Muntean, Andrew ;
Gonzalez, Maria E. ;
Kidwell, Kelley M. ;
Nikolovska-Coleska, Zaneta ;
Kleer, Celina G. .
NATURE COMMUNICATIONS, 2018, 9
[2]   Ezh1 Targets Bivalent Genes to Maintain Self-Renewing Stem Cells in Ezh2-Insufficient Myelodysplastic Syndrome [J].
Aoyama, Kazumasa ;
Oshima, Motohiko ;
Koide, Shuhei ;
Suzuki, Emi ;
Mochizuki-Kashio, Makiko ;
Kato, Yuko ;
Tara, Shiro ;
Shinoda, Daisuke ;
Hiura, Nobuhiro ;
Nakajima-Takagi, Yaeko ;
Sashida, Goro ;
Iwama, Atsushi .
ISCIENCE, 2018, 9 :161-+
[3]   Long non-coding RNA SNGH7 Is activated by SP1 and exerts oncogenic properties by interacting with EZH2 in ovarian cancer [J].
Bai, Zhuanli ;
Wu, YinYing ;
Bai, Shuheng ;
Yan, Yanli ;
Kang, Haojing ;
Ma, Wen ;
Zhang, Jiangzhou ;
Gao, Ying ;
Hui, Beina ;
Ma, Hailin ;
Li, Rong ;
Zhang, Xiaozhi ;
Ren, Juan .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (13) :7479-7489
[4]   EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation [J].
Beguelin, Wendy ;
Popovic, Relja ;
Teater, Matt ;
Jiang, Yanwen ;
Bunting, Karen L. ;
Rosen, Monica ;
Shen, Hao ;
Yang, Shao Ning ;
Wang, Ling ;
Ezponda, Teresa ;
Martinez-Garcia, Eva ;
Zhang, Haikuo ;
Zheng, Yupeng ;
Verma, Sharad K. ;
McCabe, Michael T. ;
Ott, Heidi M. ;
Van Aller, Glenn S. ;
Kruger, Ryan G. ;
Liu, Yan ;
McHugh, Charles F. ;
Scott, David W. ;
Chung, Young Rock ;
Kelleher, Neil ;
Shaknovich, Rita ;
Creasy, Caretha L. ;
Gascoyne, Randy D. ;
Wong, Kwok-Kin ;
Cerchietti, Leandro ;
Levine, Ross L. ;
Abdel-Wahab, Omar ;
Licht, Jonathan D. ;
Elemento, Olivier ;
Melnick, Ari M. .
CANCER CELL, 2013, 23 (05) :677-692
[5]   A cytosolic Ezh1 isoform modulates a PRC2-Ezh1 epigenetic adaptive response in postmitotic cells [J].
Bodega, Beatrice ;
Marasca, Federica ;
Ranzani, Valeria ;
Cherubini, Alessandro ;
Della Valle, Francesco ;
Neguembor, Maria Victoria ;
Wassef, Michel ;
Zippo, Alessio ;
Lanzuolo, Chiara ;
Pagani, Massimiliano ;
Orlando, Valerio .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2017, 24 (05) :444-+
[6]   EZH2 Inhibitor Efficacy in Non-Hodgkin's Lymphoma Does Not Require Suppression of H3K27 Monomethylation [J].
Bradley, William D. ;
Arora, Shilpi ;
Busby, Jennifer ;
Balasubramanian, Srividya ;
Gehling, Victor S. ;
Nasveschuk, Christopher G. ;
Vaswani, Rishi G. ;
Yuan, Chih-Chi ;
Hatton, Charlie ;
Zhao, Feng ;
Williamson, Kaylyn E. ;
Iyer, Priyadarshini ;
Mendez, Jacqui ;
Campbell, Robert ;
Cantone, Nico ;
Garapaty-Rao, Shivani ;
Audia, James E. ;
Cook, Andrew S. ;
Dakin, Les A. ;
Albrecht, Brian K. ;
Harmange, Jean-Christophe ;
Daniels, Danette L. ;
Cummings, Richard T. ;
Bryant, Barbara M. ;
Normant, Emmanuel ;
Trojer, Patrick .
CHEMISTRY & BIOLOGY, 2014, 21 (11) :1463-1475
[7]   EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity [J].
Campbell, John E. ;
Kuntz, Kevin W. ;
Knutson, Sarah K. ;
Warholic, Natalie M. ;
Keilhack, Heike ;
Wigle, Tim J. ;
Raimondi, Alejandra ;
Klaus, Christine R. ;
Rioux, Nathalie ;
Yokoi, Akira ;
Kawano, Satoshi ;
Minoshima, Yukinori ;
Choi, Hyeong-Wook ;
Scott, Margaret Porter ;
Waters, Nigel J. ;
Smith, Jesse J. ;
Chesworth, Richard ;
Moyer, Mikel P. ;
Copeland, Robert A. .
ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (05) :491-495
[8]   HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase [J].
Chakraborty, Abhishek A. ;
Nakamura, Eijiro ;
Qi, Jun ;
Creech, Amanda ;
Jaffe, Jacob D. ;
Paulk, Joshiawa ;
Novak, Jesse S. ;
Nagulapalli, Kshithija ;
McBrayer, Samuel K. ;
Cowley, Glenn S. ;
Pineda, Javier ;
Song, Jiaxi ;
Wang, Yaoyu E. ;
Carr, Steven A. ;
Root, David E. ;
Signoretti, Sabina ;
Bradner, James E. ;
Kaelin, William G., Jr. .
SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (398)
[9]   Engaging chromatin: PRC2 structure meets function [J].
Chammas, Paul ;
Mocavini, Ivano ;
Di Croce, Luciano .
BRITISH JOURNAL OF CANCER, 2020, 122 (03) :315-328
[10]   Unique Structural Platforms of Suz12 Dictate Distinct Classes of PRC2 for Chromatin Binding [J].
Chen, Siming ;
Jiao, Lianying ;
Shubbar, Murtada ;
Yang, Xin ;
Liu, Xin .
MOLECULAR CELL, 2018, 69 (05) :840-+